PDF(Pubmed)
Abstract：
Migraine is common in children and adolescents and can cause significant disability. There are relatively limited evidence-based treatment options available, especially when compared with treatment of migraine in adults. The Pediatric Research Equity Act requires the study of a new drug or biologic in pediatric populations. As such it is mandatory that the newest migraine treatment options available for adults be evaluated in children and adolescents. It will take years before results from clinical trials in pediatric patients become available. In the meantime, there is eagerness among clinicians to seek out the existing evidence that may help provide clarity on utilization of the newer migraine therapies in children and adolescents because many of the currently available, guideline-recommended treatments do not provide benefit for all patients. In this narrative review, the literature regarding onabotulinumtoxinA, neuromodulatory devices, calcitonin gene-related peptide (CGRP) monoclonal antibodies, 5-hydroxytryptamine (1F) agonists (i.e., ditans), and CGRP small-molecule receptor antagonists (i.e., gepants) for the treatment of migraine in children and adolescents will be summarized.
摘要：
偏头痛在儿童和青少年中很常见，可导致严重的残疾。基于证据的治疗方案相对有限，特别是与成人偏头痛的治疗相比。《儿科研究公平法》要求在儿科人群中研究新药或生物制剂。因此，必须在儿童和青少年中评估成人可用的最新偏头痛治疗方案。在儿科患者的临床试验结果可用之前需要几年的时间。同时,临床医生渴望寻找现有的证据，这些证据可能有助于澄清儿童和青少年使用较新的偏头痛疗法，就像目前可用的疗法一样，指南推荐的治疗并不能为所有患者带来益处.在这篇叙述性评论中，有关onabotulinumtoxinA的文献，神经调节装置，降钙素基因相关肽(CGRP)单克隆抗体,5-羟色胺（1F）激动剂（即ditans），将总结用于治疗儿童和青少年偏头痛的CGRP小分子受体拮抗剂(即gepants)。
